Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01220128 · ClinicalTrials.gov registry record · Phase 2
Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer
A Phase 2 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT01220128 is a Phase 2 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 66 participants.
The verdict
NCT01220128, a Phase 2 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, immunogenicity and clinical activity of a new WT1 anti-cancer immunotherapy in patients with WT1-positive Stage II or III breast cancer. The treatment will be given before surgery in combination with standard therapy.
Interventions
- DRUG Placebo
- DRUG 5-Fluorouracil
- DRUG Aromatase inhibitor
- DRUG Carboplatin AUC
- BIOLOGICAL GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2011-04-11 |
| Est. Completion | 2014-11-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01220128
The ClinicalTrials.gov registry entry for NCT01220128 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01220128 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01220128 about?
NCT01220128 is a clinical study titled "Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer". The purpose of this study is to evaluate the safety, immunogenicity and clinical activity of a new WT1 anti-cancer immunotherapy in patients with WT1-positive Stage II or III breast cancer. The treatment will be given before surgery in combination with standard therapy.
What is the current status of trial NCT01220128?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2011-04-11. Estimated completion is 2014-11-14.
What interventions are being tested in trial NCT01220128?
The interventions under investigation include: Placebo (DRUG), 5-Fluorouracil (DRUG), Aromatase inhibitor (DRUG), Carboplatin AUC (DRUG), GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A (BIOLOGICAL).
Who is sponsoring clinical trial NCT01220128?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.